Mereo BioPharma Group plc MREO

MREO Company Overview

Mereo BioPharma Group plc is a United Kingdom–based biopharmaceutical company focused on the development of therapeutics for rare diseases and oncology. The company primarily operates in the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on advancing clinically differentiated therapies that address conditions with significant unmet medical needs. Mereo’s business model centers on acquiring, licensing, and developing mid- to late-stage drug candidates, often leveraging partnerships with larger pharmaceutical companies and academic institutions to support commercialization and clinical development.

The company’s principal value drivers are its pipeline assets targeting rare genetic disorders and cancer-related indications. Key programs have included treatments for osteogenesis imperfecta, alpha-1 antitrypsin deficiency–associated lung disease, and oncology therapies targeting immune and cellular pathways. Mereo was founded in 2015 through the assembly of assets acquired from larger pharmaceutical organizations and has evolved into a publicly traded biotechnology company listed on Nasdaq under the ticker MREO. Its strategy has emphasized capital-efficient development through external collaborations, selective portfolio prioritization, and licensing arrangements.